Event Information
Lessons from the Pandemic:
Influenza A (H1N1) and the Biotech Industry
One year ago this April, a new and deadly flu emerged in Mexico that would prove to be one of the most pervasive and virulent influenza strains to emerge in 100 years. As we approach the year anniversary of swine flu entering the public lexicon, join BIOCOM as we hear from influenza experts and discuss lessons learned from this pandemic. How did public health agencies from around the world handle the outbreak? How will vaccine production be handled in the future? And what does the biotech industry need to do better to ensure its ability to respond to public health emergencies like this in the future?
Moderator:
Tom Fudge, Health Reporter, KPBS
Speakers:
Brian Plew, Head of Public Health, Life Technologies
Brian Plew leads Life Technologies global initiatives for human epidemiological testing. Over the past five years, Plew has led Life Technologies' businesses focused on molecular methods for the detection of pathogens from biothreat and naturally emerging infectious disease. Prior to leading Public Health, Plew led the Biosecurity and Environmental Testing business at Applied Biosystems. Plew joined Applied Biosystems in 2002 as a director in platform systems research and development.
Larry R. Smith, Ph.D., Vice President, Vaccine Research, Vical Incorporated
Larry R. Smith, Ph.D., joined us as Executive Director, Vaccinology in September 2003, and was named Vice President, Vaccine Research in October 2006. Dr. Smith was Director of Viral Vaccines Research at Wyeth Vaccines, where he oversaw the immunogenicity testing of various viral vaccines including a number of recombinant viral vectors. Prior to joining Wyeth in 1996, Dr. Smith was a Scientific Investigator at Immune Response Corporation, where he identified autoreactive T cell targets in psoriasis and multiple sclerosis which led to the clinical testing of several therapeutic vaccine candidates. Dr. Smith received a B.S. degree in Biology from Purdue University, a Ph.D. in Microbiology and Immunology from the University of Texas Medical Branch, and was a postdoctoral fellow in the Immunology Department at Scripps Clinic and Research Foundation.
John D. Tamerius, Ph.D., SVP, Clinical and Regulatory Affairs, Quidel Corporation
John D. Tamerius, Ph.D. became our Senior Vice President, Clinical/Regulatory Affairs in November 2008. From June 2005 to November 2008, he was our Vice President, Clinical/Regulatory Affairs. Dr. Tamerius has been an integral part of Quidel for 25 years. Prior to serving as VP, Clinical/Regulatory Affairs he previously held a variety of executive roles including responsibility for research and development and general management of Northern California operations. Dr. Tamerius originally joined Quidel in 1983 with the acquisition of Cytotech, Inc. where he was president. Prior to working at Cytotech, Dr. Tamerius was a research associate at Scripps Clinic and Research Foundation. Dr. Tamerius has been awarded a Bachelor of Science, a Master of Science, and a Ph.D. in Microbiology and Immunology, all from the University of Washington.
| When | Wednesday, March 17, 2010 7:00 a.m. - 9:00 a.m. |
 Add to Calendar |
| RSVP | Tuesday, March 16, 2010 12:00 p.m. |
| Where |
Hyatt Regency La Jolla 3777 La Jolla Village Drive San Diego, California 92122 |
 Get Driving Directions |
| Planner | Valerie Sanderson (858) 455-0300 Ext 112 |